Skip to main content

Psoriatic arthritis

      RT @RichardPAConway: Behrens et al. Izokibep (small molecular size IL17Ai, suggested to abrogate issues with tissue dist
      2 years 5 months ago
      Behrens et al. Izokibep (small molecular size IL17Ai, suggested to abrogate issues with tissue distribution of monoclonal abs) in PsA. ACR50 52% in 80mg, 48% in 40mg, 13% in PBO. @RheumNow #EULAR2022 https://t.co/FUS50ax79C https://t.co/e1n1RbNw1b
      RT @RichardPAConway: Michielsens et al T2T tapering of TNFi in AxSpA and PsA. 72% tapered, 28% discontinued TNFi. Month
      2 years 5 months ago
      Michielsens et al T2T tapering of TNFi in AxSpA and PsA. 72% tapered, 28% discontinued TNFi. Month 12 LDA 69% vs 73%.Month 12 dose 53% vs 91%. Flares 85% vs 78%. Needed more NSAID 54% vs 24% and steroid 30% vs 17%. @RheumNow #EULAR2022 OP0261 https://t.co/EDBPOgg4sX https://t.co/ckPqaTdm4B
      RT @doctorRBC: Large 5 country cohort study - No increased risk of hematologic malignancies (lymphoid or myeloid) in PsA
      2 years 5 months ago
      Large 5 country cohort study - No increased risk of hematologic malignancies (lymphoid or myeloid) in PsA pts treated with TNFi. In PsA overall compared to general population - moderately increased underlying risk of hematologic malignancies. @RheumNow #EULAR2022 ABST#OP0257 https://t.co/P846RupitR
      RT @Yuz6Yusof: #OP0249 #EULAR2022 Dr Machado presented pooled data >5000 pts. Poor #COVID outcomes in Pso, PsA and A
      2 years 5 months ago
      #OP0249 #EULAR2022 Dr Machado presented pooled data >5000 pts. Poor #COVID outcomes in Pso, PsA and AxSpa were associated with the usual suspects: Age, male, high disease activity and comorbidities. No specific bDMARDs was associated. Good news for our patients @RheumNow https://t.co/itzmwqKCrH
      RT @doctorRBC: Ok to taper?
      In PsA and AxSpA pts on TNFi, a T2T w/ tapering strategy was non-inferior to a T2T w/o taper
      2 years 5 months ago
      Ok to taper? In PsA and AxSpA pts on TNFi, a T2T w/ tapering strategy was non-inferior to a T2T w/o tapering. 69% of tapered group remained in LDA, 73% no-taper group in LDA after 12 months. Taper group did use more NSAIDs, cDMARDs, steroids @RheumNow #EULAR2022 ABST#OP0261
      RT @doctorRBC: Deep learning can be used to distinguish seropositive RA from seronegative RA and PsA based on MRI.
      Earl
      2 years 5 months ago
      Deep learning can be used to distinguish seropositive RA from seronegative RA and PsA based on MRI. Early changes in PsO may suggest a PsA-like MRI pattern may be present! Is this how we predict which PsO -> PsA? @RheumNow #EULAR2022 ABST#OP0292 https://t.co/NGfFkSqlaM
      RT @synovialjoints: The third SARS-CoV-2 vaccine in IMID (RA, SpA, PsA, UC, CD) patients on immunosuppression improves t
      2 years 5 months ago
      The third SARS-CoV-2 vaccine in IMID (RA, SpA, PsA, UC, CD) patients on immunosuppression improves the serologic response follow the first two vaccine doses and allowed them to close the gap compared to the two-dose vaccinated controls #EULAR2022 @RheumNow OP0192 Jyssum et al
      RT @drdavidliew: For psoriasis +MSK pain, should we be chasing synovitis/enthesitis on ultrasound?

      PsO pts with MSK pai
      2 years 5 months ago
      For psoriasis +MSK pain, should we be chasing synovitis/enthesitis on ultrasound? PsO pts with MSK pain n=79 USS inflamm in 47% Site-spec correlate only OR 3.1 Even if we act on USS: PsA Rx is systemic, so overall impression is good enough anyway? POS0131 #EULAR2022 @RheumNow https://t.co/O3P7J2Rskw